Microbiota dysbiosis in inflammatory bowel diseases: In silico investigation of the oxygen hypothesis

BMC Systems Biology

Volumn 11, Issue 1, 2017, Pages

  Henson, Michael A ^a   Phalak, Poonam ^a  

^a University of Massachusetts   (United States)

Author keywords

Biofilms; Gut microbiota; Inflammatory bowel disease; Metabolic modeling

Indexed keywords

OXYGEN;

BACTEROIDES THETAIOTAOMICRON; BIOFILM; BIOLOGY; COMPUTER SIMULATION; DYSBIOSIS; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; METABOLISM; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY;

BACTEROIDES THETAIOTAOMICRON; BIOFILMS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DYSBIOSIS; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MICROBIOTA; OXYGEN;

EID: 85039844696     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/s12918-017-0522-1     Document Type: Article

References (67)

1. Danese S, Fiocchi C. Ulcerative colitis. New England J Med. 2011; 365(18):1713-25.
2. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012; 380(9853):1590-605.
3. Colombel JF, Mahadevan U. Inflammatory bowel disease 2017: Innovations and changing paradigms. Gastroenterology. 2017; 152(2):309-12.
4. Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015; 110(1):114.
5. Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn's disease. Gastroenterol Hepatol. 2010; 6(9):587.
6. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016; 22(3 Suppl):51-60.
7. Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?World J Gastroenterol: WJG. 2014; 20(5):1192.
8. Thompson JA, Oliveira RA, Xavier KB. Chemical conversations in the gut microbiota. Gut Microbes. 2016; 7(2):163-70.
9. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016; 535(7610):75-84.
10. DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016; 22(5):1137.
11. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015; 31(1):69.
12. Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol. 2015; 69:445-61.
13. Byrne C, Chambers E, Morrison D, Frost G. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obes. 2015; 39(9):1331-8.
14. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J lipid Res. 2013; 54(9):2325-40.
15. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. In: Seminars in Immunopathology. vol. 37, No.1. Berlin Heidelberg: Springer: 2015. p. 47-55.
16. Lu C, Zhao X, Lai MA, Lopez-Yglesias AH, Quarles EK, Lo C, Smith KD. Commensal E. coli induced colonization resistance against mucosal Salmonella infection. Am Assoc Immnol. 2016;:66-11.
17. Ahmed I, Roy BC, Khan SA, Septer S, Umar S. Microbiome, metabolome and inflammatory bowel disease. Microorganisms. 2016; 4(2):20.
18. Øyri SF, Muzes G, Sipos F. Dysbiotic gut microbiome: A key element of Crohn's disease. Comp Immunol Microbiol Infect Dis. 2015; 43:36-49.
19. Rigottier-Gois L. Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis. ISME J. 2013; 7(7):1256.
20. Zhu H, Li YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med. 2012; 237(5):474-80.
21. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A, Grunberg S, Baldassano RN, Lewis JD, Li H, et al.Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology. 2014; 147(5):1055-63.
22. Hartman AL, Lough DM, Barupal DK, Fiehn O, Fishbein T, Zasloff M, Eisen JA. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci. 2009; 106(40):17187-92.
23. Kelly CJ, Zheng L, Campbell EL, Saeedi B, Scholz CC, Bayless AJ, Wilson KE, Glover LE, Kominsky DJ, Magnuson A, et al.Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015; 17(5):662-71.
24. Miquel S, Leclerc M, Martin R, Chain F, Lenoir M, Raguideau S, Hudault S, Bridonneau C, Northen T, Bowen B, et al.Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio. 2015; 6(2):00300-15.
25. Baughn AD, Malamy MH. The strict anaerobe Bacteroides fragilis grows in and benefits from nanomolar concentrations of oxygen. Nature. 2004; 427(6973):441.
26. Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, Torres TP, Byndloss AJ, Faber F, Gao Y, et al.Microbiota-activated ppar- γ signaling inhibits dysbiotic enterobacteriaceae expansion. Science. 2017; 357(6351):570-5.
27. De Vos WM. Microbial biofilms and the human intestinal microbiome. npj Biofilms Microbiomes. 2015; 1:15005.
28. Macfarlane S, Bahrami B, Macfarlane GT. Mucosal biofilm communities in the human intestinal tract. Adv Appl Microbiol. 2011; 75:111-43.
29. von Rosenvinge EC, O'May GA, Macfarlane S, Macfarlane GT, Shirtliff ME. Microbial biofilms and gastrointestinal diseases. Pathog Dis. 2013; 67(1):25-38.
30. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci. 2012; 109(2):594-9.
31. Levy R, Borenstein E. Metabolic modeling of species interaction in the human microbiome elucidates community-level assembly rules. Proc Natl Acad Sci. 2013; 110(31):12804-9.
32. Henson MA, Hanly TJ. Dynamic flux balance analysis for synthetic microbial communities. IET Syst Biol. 2014; 8(5):214-29.
33. Heinken A, Sahoo S, Fleming RM, Thiele I. Systems-level characterization of a host-microbe metabolic symbiosis in the mammalian gut. Gut microbes. 2013; 4(1):28-40.
34. Heinken A, Khan MT, Paglia G, Rodionov DA, Harmsen HJ, Thiele I. Functional metabolic map of Faecalibacterium prausnitzii, a beneficial human gut microbe. J Bacteriol. 2014; 196(18):3289-302.
35. Baumler DJ, Peplinski RG, Reed JL, Glasner JD, Perna NT. The evolution of metabolic networks of E. coli. BMC Syst Biol. 2011; 5(1):182.
36. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut microbes. 2012; 3(4):289-306.
37. Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013; 11(9):639.
38. Dai ZL, Wu G, Zhu WY. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. Front Biosci. 2011; 16(1):1768-86.
39. Larocque M, Chénard T, Najmanovich R. A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors. BMC Syst Biol. 2014; 8(1):117.
40. Horn H, Lackner S. Modeling of biofilm systems: a review. In: Productive Biofilms. Springer International Publishing: 2014. p. 53-76.
41. Henson MA, Phalak P. Byproduct cross feeding and community stability in an in silico biofilm model of the gut microbiome. Processes. 2017; 5(1):13.
42. Khan MT, van Dijl JM, Harmsen HJ. Antioxidants keep the potentially probiotic but highly oxygen-sensitive human gut bacterium Faecalibacterium prausnitzii alive at ambient air. PloS ONE. 2014; 9(5):96097.
43. Stewart PS. Diffusion in biofilms. J Bacteriol. 2003; 185(5):1485-91.
44. Stewart PS. A review of experimental measurements of effective diffusive permeabilities and effective diffusion coefficients in biofilms. Biotech Bioeng. 1998; 59(3):261-72.
45. Meadows AL, Karnik R, Lam H, Forestell S, Snedecor B. Application of dynamic flux balance analysis to an industrial Escherichia coli fermentation. Metab Eng. 2010; 12(2):150-60.
46. Carlson R, Srienc F. Fundamental Escherichia coli biochemical pathways for biomass and energy production: identification of reactions. Biotech Bioeng. 2004; 85(1):1-19.
47. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol. 2011; 9(4):279-90.
48. Phalak P, Chen J, Carlson RP, Henson MA. Metabolic modeling of a chronic wound biofilm consortium predicts spatial partitioning of bacterial species. BMC Syst Biol. 2016; 10(1):90.
49. Gomez JA, Hoffner K, Barton PI. DFBAlab: a fast and reliable MATLAB code for dynamic flux balance analysis. BMC Bioinforma. 2014; 15:409.
50. Khan MT, Duncan SH, Stams AJ, Van Dijl JM, Flint HJ, Harmsen HJ. The gut anaerobe Faecalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. ISME J. 2012; 6(8):1578.
51. Khan MT, Browne WR, van Dijl JM, Harmsen HJ. How can Faecalibacterium prausnitzii employ riboflavin for extracellular electron transfer? 2012:1433-1440.
52. Kuroki F, Iida M, Tominaga M, Matsumoto T, Hirakawa K, Sugiyama S, Fujishima M. Multiple vitamin status in Crohn's disease. Dig Dis Sci. 1993; 38(9):1614-8.
53. Dixon LJ, Kabi A, Nickerson KP, McDonald C. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2015; 21(4):912.
54. Haskey N, Gibson DL. An examination of diet for the maintenance of remission in inflammatory bowel disease. Nutrients. 2017; 9(3):259.
55. Ozbudak EM, Thattai M, Lim HN, Shraiman BI, Van Oudenaarden A. Multistability in the lactose utilization network of escherichia coli. Nature. 2004; 427(6976):737-40.
56. Card T, Logan R, Rodrigues L, Wheeler J. Antibiotic use and the development of Crohn's disease. Gut. 2004; 53(2):246-50.
57. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, et al.The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014; 15(3):382-92.
58. Van Hoek MJ, Merks RM. Emergence of microbial diversity due to cross-feeding interactions in a spatial model of gut microbial metabolism. BMC Syst Biol. 2017; 11(1):56.
59. Kettle H, Louis P, Holtrop G, Duncan SH, Flint HJ. Modelling the emergent dynamics and major metabolites of the human colonic microbiota. Environ Microbiol. 2015; 17(5):1615-30.
60. Muñoz-Tamayo R, Laroche B, Walter É, Doré J, Leclerc M. Mathematical modelling of carbohydrate degradation by human colonic microbiota. J Theor Biol. 2010; 266(1):189-201.
61. Heinken A, Thiele I. Systematic prediction of health-relevant human-microbial co-metabolism through a computational framework. Gut Microbes. 2015; 6(2):120-30.
62. Ji B, Nielsen J. From next-generation sequencing to systematic modeling of the gut microbiome. Front Genet. 2015; 6.
63. Shoaie S, Nielsen J. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling. Front Genet. 2014; 5.
64. Thiele I, Heinken A, Fleming RM. A systems biology approach to studying the role of microbes in human health. Curr Opin Biotechnol. 2013; 24(1):4-12.
65. Donelli G, Vuotto C, Cardines R, Mastrantonio P. Biofilm-growing intestinal anaerobic bacteria. FEMS Immunol Med Microbiol. 2012; 65(2):318-25.
66. Macfarlane S, Dillon J. Microbial biofilms in the human gastrointestinal tract. J Appl Microbiol. 2007; 102(5):1187-96.
67. Ouwerkerk JP, de Vos WM, Belzer C. Glycobiome: bacteria and mucus at the epithelial interface. Best Practice Res Clinical Gastroenterol. 2013; 27(1):25-38.